Insulin Secretagogue Drugs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 28, 2008
app pub date -
Dec 14, 2004
filing date -
Jun 23, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Demanded is an insulin secretagogue that alleviates side effects, such as acceleration of obesity and cells so as not to be detrimental to insulin secretion .beta. capability. The invention provides an insulin secretagogue agent not only dependent on glucose but also responsive to elevated blood sugar levels, comprising an effective amount of a substance having the activity of PPAR .delta. activation. This insulin secretagogue simultaneously exerts anti-obesity activity, serum cholesterol reducing activity useful for the treatment and prevention of arteriosclerosis, etc. and insulin resistance ameliorating activity.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully